‘A True Seat At The Table’ – Irish Industry Leader Sets Out Aspirations For New Pricing Deal
Teva’s Paul Neill, Chair Of Medicines For Ireland, Talks About Priorities For 2025 Agreement
With a fresh pricing deal on the horizon, Medicines for Ireland chair and Teva country head Paul Neill talks to Generics Bulletin about the need for the Irish off-patent industry to have “a true seat at the table” and secure an agreement with the country’s government that better reflects the specificities of the generics and biosimilars market.
